Literature DB >> 30472711

Antibodies Against M-Type Phospholipase Receptor and Prediction of Outcome in Membranous Nephropathy: We are Not There Yet.

Jack F M Wetzels1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30472711      PMCID： PMC6381871          DOI： 10.1159/000494661

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN： 0250-8095            Impact factor:   3.754


× No keyword cloud information.
  10 in total

1.  Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up.

Authors:  Anne-Els van de Logt; Julia M Hofstra; Jack F M Wetzels
Journal:  Kidney Int       Date:  2015-06       Impact factor: 10.612

2.  Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.

Authors:  Anne-Els van de Logt; Karine Dahan; Alexandra Rousseau; Renate van der Molen; Hanna Debiec; Pierre Ronco; Jack Wetzels
Journal:  Kidney Int       Date:  2018-04       Impact factor: 10.612

3.  Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy.

Authors:  Zhen Qu; Mu-Fan Zhang; Zhao Cui; Jia Wang; Miao Wang; Yi-Miao Zhang; Fang Wang; Xin Wang; Li-Qiang Meng; Xu-Yang Cheng; Gang Liu; Ming-Hui Zhao
Journal:  Am J Nephrol       Date:  2018-11-23       Impact factor: 3.754

Review 4.  A Proposal for a Serology-Based Approach to Membranous Nephropathy.

Authors:  An S De Vriese; Richard J Glassock; Karl A Nath; Sanjeev Sethi; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2016-10-24       Impact factor: 10.121

5.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.

Authors:  Laurence H Beck; Ramon G B Bonegio; Gérard Lambeau; David M Beck; David W Powell; Timothy D Cummins; Jon B Klein; David J Salant
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

6.  Increased expression of lysosome membrane protein 2 in glomeruli of patients with idiopathic membranous nephropathy.

Authors:  Ilse M Rood; Michael L Merchant; Daniel W Wilkey; Terry Zhang; Vlad Zabrouskov; Johan van der Vlag; Henry B Dijkman; Brigith K Willemsen; Jack F Wetzels; Jon B Klein; Jeroen K Deegens
Journal:  Proteomics       Date:  2015-09-28       Impact factor: 3.984

7.  Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy.

Authors:  Marilina Tampoia; Francesca Migliucci; Chiara Villani; Letizia Abbracciavento; Michele Rossini; Ruggiero Fumarulo; Loreto Gesualdo; Vincenzo Montinaro
Journal:  J Nephrol       Date:  2018-09-05       Impact factor: 3.902

8.  Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.

Authors:  Julia M Hofstra; Hanna Debiec; Colin D Short; Timotheé Pellé; Robert Kleta; Peter W Mathieson; Pierre Ronco; Paul E Brenchley; Jack F Wetzels
Journal:  J Am Soc Nephrol       Date:  2012-09-06       Impact factor: 10.121

9.  Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.

Authors:  Piero Ruggenenti; Hanna Debiec; Barbara Ruggiero; Antonietta Chianca; Timothee Pellé; Flavio Gaspari; Flavio Suardi; Elena Gagliardini; Silvia Orisio; Ariela Benigni; Pierre Ronco; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2015-03-24       Impact factor: 10.121

10.  Clinical implications of pathological features of primary membranous nephropathy.

Authors:  Xiao-Dan Zhang; Zhao Cui; Mu-Fan Zhang; Jia Wang; Yi-Miao Zhang; Zhen Qu; Xin Wang; Jing Huang; Fang Wang; Li-Qiang Meng; Xu-Yang Cheng; Su-Xia Wang; Gang Liu; Ming-Hui Zhao
Journal:  BMC Nephrol       Date:  2018-08-28       Impact factor: 2.388
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.